BSEBeryl Drugs LtdMinimalNeutral
Announced Wed, 9 Apr · 13:31 IST

COMPLIANCE CERTIFICATE UNDER REGULATION 74(5)

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Beryl Drugs Ltd has submitted a compliance certificate to BSE under Regulation 74(5) of the SEBI Depositories Regulations for the quarter ended 31 March 2025. The certificate, issued by their Registrar and Transfer Agent Adroit Corporate Services Pvt. Ltd., confirms that all share certificates received for dematerialization during Q4 FY25 were duly processed, confirmed to the depositories, mutilated, and cancelled within the stipulated 15-day timeline, with the depository names updated in the register of members. A separate Regulation 7(3) compliance certificate regarding physical and electronic share transfer facilities was also enclosed.

Likely market impact

This is a routine regulatory compliance filing with no material impact on the company's financials, operations, or stock price. It simply confirms that the company's share transfer and dematerialization processes are functioning as required by SEBI rules.